Pharmaceuticals Companies By Pb Ratio

Price To Book
Price To BookEfficiencyMarket RiskExp Return
1VRCA Verrica Pharmaceuticals
238.54
(0.20)
 4.74 
(0.95)
2TELO Telomir Pharmaceuticals, Common
194.86
 0.05 
 6.71 
 0.33 
3EOLS Evolus Inc
151.91
 0.03 
 4.80 
 0.15 
4AXSM Axsome Therapeutics
108.84
 0.12 
 4.28 
 0.53 
5RDHL Redhill Biopharma
101.34
(0.26)
 4.20 
(1.10)
6AMRX Amneal Pharmaceuticals, Class
86.1
 0.03 
 2.14 
 0.07 
7LLY Eli Lilly and
55.78
 0.13 
 1.83 
 0.24 
8VRNA Verona Pharma PLC
39.15
 0.25 
 3.34 
 0.84 
9CARA Cara Therapeutic
32.39
 0.09 
 10.74 
 1.01 
10SCLX Scilex Holding
28.85
(0.22)
 4.86 
(1.07)
11PHAT Phathom Pharmaceuticals
25.37
(0.20)
 3.99 
(0.79)
12OPTN OptiNose
24.26
(0.09)
 4.99 
(0.46)
13ETON Eton Pharmaceuticals
23.25
 0.03 
 4.73 
 0.15 
14DRRX Durect
20.15
(0.01)
 5.45 
(0.05)
15NVO Novo Nordisk AS
19.96
(0.06)
 3.42 
(0.22)
16BHC Bausch Health Companies
18.78
(0.07)
 3.11 
(0.22)
17HROW Harrow Health
17.78
(0.20)
 3.30 
(0.66)
18ZTS Zoetis Inc
15.06
(0.03)
 1.55 
(0.05)
19LQDA Liquidia Technologies
12.34
 0.21 
 2.53 
 0.53 
20ITCI Intracellular Th
11.91
 0.16 
 4.95 
 0.80 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.